Cases & Deals

  • Home
  • Practices
  • Pfizer acquires Vicuron Pharmaceuticals for $1.9 billion

Share

Pfizer acquires Vicuron Pharmaceuticals for $1.9 billion

September 2005

Client(s) Pfizer, Inc.

Jones Day represented Pfizer in its $1.9 billion acquisition of Vicuron Pharmaceuticals (Nasdaq NM:MICU), a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.